Corvus Pharmaceuticals Inc expected to post a loss of 12 cents a share - Earnings Preview
06/05/2025 21:36
Corvus Pharmaceuticals Inc CRVS.OQ CRVS.O is expected to show no change in quarterly revenue when it reports results on May 8 for the period ending March 31 2025 ​LSEG's mean analyst estimate for Corvus Pharmaceuticals Inc is for a loss of 12 cents per share. The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. ​ Wall Street's median 12-month price target for Corvus Pharmaceuticals Inc is $13.00​, above​ its last closing price of $3.57. ​​​ Previous quarterly performance (using preferred earnings measure in US dollars). ​
| QUARTER ENDING | STARMINESMARTESTIMATEÂŪ | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Dec. 31 2024 | -0.12 | -0.12 | -0.18 | Missed | -50.5 |
| Sep. 30 2024 | -0.11 | -0.12 | -0.60 | Missed | -414.6 |
| Jun. 30 2024 | -0.12 | -0.11 | -0.04 | Beat | 65.2​ |
| Mar. 31 2024 | -0.14 | -0.12 | -0.12 | Met | 0 |
| ​​Dec. 31 2023 | -0.12 | -0.14 | Missed | -17.6 | |
| Sep. 30 2023 | -0.12 | -0.12 | -0.12 | Met | 1.6​ |
| Jun. 30 2023 | -0.16 | -0.14 | -0.14 | Met | -0.5 |
| Mar. 31 2023 | -0.16 | -0.16 | -0.17 | Missed | -8.3 |
Recent news on Corvus Pharmaceuticals
See all newsBrief: Corvus Pharmaceuticals Announces Initiation Of Phase 1B Clinical Trial Of Soquelitinib For Patients With Hidradenitis Suppurativa
Corvus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Toll Brothers, TG Therapeutics, CECO Environmental